It is essential to know that the impact of the environment on peptide’s large scale production is quite significant in the modern age. The Vice President of Solvay company’s strategic and global business development section, Mimoun Ayoub, stated that 20 kilograms’ production of a peptide (18-residue) tends to generate close to 300 metric tons. These metric tons are produced through the use of other waste materials and solvents. The waste brought forward gets managed and magnified for an organization that is already operating many commercial peptides. Furthermore, the company also handles the waste separation logistics, disposable, and storage that can act as a massive burden at times.

Since the crude peptide purification happens to be the driving element behind the manufacturing cost, Dr Ayoub states that purity in its initial terms of such a crude product is an essential factor, which reduces processing costs. The professor also suggested that such decisions should be finalized based on case-by-case. Moreover, it should also have a channelled understanding of every approach's limitations and advantages, along with the potential regularity obstacles. So, let’s do a detailed rundown of some strategies that can help in optimizing peptide synthesis services for good.

Pay close attention to minor details.

Both purification and synthesis evolution technology and the rate at which customers are transforming give way to innovation. Another PhD scholar and a process development expert at PolyPeptide Group, Jan Pawlas, stated two of the overarching trends. One is the increased amount of focus on peptide manufacturing’s economic aspects, and the second is the demand for short delivery times.
Image source:

The key is to achieve efficient conversion and optimize peptide process development around every amino acid coupling. Such a process also helps in producing crude synthetic peptides that have high purity levels. This further minimizes downstream processing demands. If you talk about traditional polystyrene bead manufacturing methods, functionalized monomers’ copolymerization tends to be an ideal process that could improve large-scale peptide synthesis yields. It also cuts short the production times.

Protein or long peptide?

Synthetic challenges tend to increase when the therapeutic peptides’ length increases. One of the senior group leaders, Almac Sciences, GMP peptides, and Dr Hazel Moncrieff, states that the growing peptides are compounded if there are possible faults in the addition of amino acids. Such a process can also compromise the final product’s quality.

One of the vital factors that help produce long peptides is selecting resins to minimize aggression and optimize the forming peptide’s solubility. Yet another crucial factor is product characterization found post-synthesis along with the requirement for high analytical methods like LC/MS and UPLC. That is to draw the differences between impurities and full-length peptides. Moreover, these are shortened peptides that do not have the complete amino acids’ complement.

One of the departments, Almac Sciences, tends to offer the cGMP production for long peptides through the process of utilizing peptide synthesizers that are solid-phase automated. One of the peptide manufacturers, Bachem, gave a presentation highlighting an increased complexity of medicines that fall under peptides. The chief marketing officer, Lester Mills, credited the much-enhanced analytical techniques to processing peptide batches. UPLC is a vital part of it that helps in providing the capability to solve such impurities. As a result, the method improves the process efficiency of longer peptides’ production and challenging sequences.

Applying Six Sigma

A manufacturing process and peptide synthesis method can have around 50 steps upwards, further introducing an extended margin for faults. But, it also offers a significant opportunity to optimize the process. Suppose you compare the process with 50+ steps with some synthetic methods that have around 96%–98% product yields. In that case, a meagre product will be available to accommodate and recover by the end of each process.

Amid the system of peptide manufacturing, you require around 99+ per cent yields under every step. Moreover, Dr Didier Monnaie states that there’s a spare room for any error to occur. 

The market front remains robust.

There is a significant rise in the number of peptide manufacturing projects globally. This has not only given researchers and manufacturing companies an edge but also added to their growing pipelines. The amount of development projects underway at Bachem’s phase III of preclinical has undoubtedly increased from around 120 in the year 2009 to close to 140 in 2010. The phase III project also experienced from 16 to 25. 

Image source:

Similarly, the manufacturing projects that produced peptides climbed from figure 71 to 86. With recent advancements in manufacturing methods, optimizing peptide synthesis has witnessed significant growth. More companies are available in the market to help you find an approach for such a synthesis system. Moreover, the figures for therapeutic peptides in 2010 totalled around $15 billion, nearly $200 million for research markets, and approximately $600 million for peptide APIs.